Genomics

PROVIDENCE – November 05, 2026 -- Electronic Genome Mapping (EGM) detected every abnormality identified by standard cytogenetic testing in an initial study, according to researchers from Augusta University and The University of Texas MD Anderson Cancer Center. They will present the findings at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, November 10-14 in Seattle, Nabsys 2.0, LLC said.

Augusta and MD Anderson pathologists present EGM data on November 13

Ravindra Kolhe, M.D., Ph.D., Professor and Chair of Pathology at Augusta University, and Rashmi Kanagal-Shamanna, M.D., Professor of Hematopathology and Molecular Diagnostics at MD Anderson, will present at the Innovation Spotlight Session (stage 1). The slot runs 9:30-10:00 a.m. PT on Friday, November 13. The talk is titled "Electronic Genome Mapping for Structural Variant Detection: Implications for Advancing Clinical Research in Heme Malignancies."

Singapore – November 02, 2026 -- Ultima Genomics' UG200 Sequencing Platform has been selected for the SG-INSIGHT cohort of Phase III of Singapore's National Precision Medicine (NPM) program, which will cover about 450,000 individuals. The company calls it its first major win supporting a national-scale clinical whole genome sequencing initiative. Financial terms were not disclosed.

Phase III targets nearly one in 10 Singapore residents

NPM Phase III is about 4.5 times the size of Phase II, which sequenced 100,000 Singaporeans. The new phase also shifts from healthy individuals to patients across a wide spectrum of health conditions. Participants will come from Singapore's three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth.

Global – October 27, 2026 -- The Truveta Genome Project aims to build the largest and most diverse de-identified database of exome-wide genomic data linked to high-fidelity clinical data ever assembled, according to a statement from a Truveta executive who joined the company earlier this year.

Health systems founded Truveta during the pandemic to speed up learning

Leading health systems created Truveta during the global pandemic around one premise: healthcare should learn faster. Patient experiences, clinical insights and research findings are meant to feed a shared resource rather than stay siloed within single institutions.

United States – October 27, 2026 -- Truveta aims to enroll tens of millions of consenting participants in the Truveta Genome Project. The goal is the largest and most diverse database of genotypic and phenotypic information ever assembled, according to Kristin Rand, the company's Senior Director of Genomics Partnerships.

The project has moved from planning to enrolling participants and collecting samples, roughly 15 months after Truveta announced it. It builds a consented, de-identified genomic dataset linked with longitudinal clinical data, treatments and outcomes. Truveta has not disclosed current enrollment figures or the number of participating health systems.

San Mateo – October 19, 2026 -- Helix will present three-year outcomes from CDC Tier 1 genomic screening of 527,000 participants at the opening plenary of the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20-24 in Montreal. The company says its GenoSphereTM resource now holds more than 620,000 paired EHR, claims and genomics records.

Helix Research Network supplies the plenary data from 17 health systems

The plenary study draws on the Helix Research Network (HRN), which Helix describes as the world's largest precision health network. All 17 member health systems offer CDC Tier 1 primary screening to every patient who enrolls in research. The study examines how surfacing previously undiagnosed genetic risk can improve screening and preventive care across diverse health systems.

Cassie Hajek, MD, Medical Director, will deliver the talk on Tuesday, October 20, from 5:57 to 6:15 p.m. ET in Room 517.

Providence – October 16, 2026 -- Nabsys 2.0, LLC has released RepX, a cloud-based pipeline that can analyze up to 23 disease-associated repeat expansion loci in a single, low-cost run, according to the company.

RepX is available through the Nabsys Navigator cloud platform. It processes Electronic Genome Mapping (EGM) data generated on the OhmX Platform.

EGM reads single ultra-long DNA molecules without amplification or ligation

Repeat expansions are linked to numerous inherited disorders but remain difficult to characterize. EGM analyzes individual ultra-long DNA molecules without amplification or ligation, which avoids biases tied to those processes. Researchers can examine the distribution of expansion sizes and investigate repeat instability within each allele.

Ipswich, Mass. – October 16, 2026 -- New England Biolabs (NEB) has secured co-exclusive rights to sell seqWell's TnX Transposase and the right to manufacture the enzyme and include it in NEB kits and products, under a strategic partnership announced alongside the commercial launch of TnX Transposase (Unloaded).

NEB gains sales and manufacturing rights under the agreement

The deal gives NEB two rights: co-exclusive sales of TnX Transposase, and manufacturing of TnX for incorporation into its own kits. seqWell keeps selling TnX-based library preparation kits through its own channel.

NEB cites more than 50 years of enzyme manufacturing and quality control as its contribution. seqWell supplies the engineered enzyme and its transposase expertise.

Dallas – October 15, 2026 -- Colossal Biosciences has unveiled GenoMorph, an in-house AI platform that identified an estimated 2,300 candidate regulatory DNA elements linked to avian beak size and shape, giving its dodo de-extinction program a prioritized list of targets for experimental testing.

GenoMorph finds 653 beak-size and 1,698 beak-thickness candidates

The platform combines comparative genomics, developmental biology and high-resolution 3D morphology to predict which regulatory elements are active during development. It then ranks those most strongly associated with differences in physical form. Regulatory DNA controls when, where and how strongly genes are activated, and it helps shape traits such as skull and beak structure.

Olympia – October 14, 2026 -- Fungi Perfecti, LLC has published the first complete genome of the endangered Agarikon fungus, a 28.76-megabase nuclear assembly estimated to be 99.4% complete, in the peer-reviewed journal G3: Genes, Genomes, Genetics.

The study, led by mycologist Paul Stamets and company scientists, is titled "Genomic characterization of the endangered medicinal polypore agarikon (Laricifomes officinalis syn. Fomitopsis officinalis)." Until now, Agarikon lacked a comprehensive genomic reference for genetic investigation.

Researchers annotate 8,717 predicted genes in the Agarikon nuclear genome

Fungi Perfecti researchers assembled and annotated both the nuclear and mitochondrial genomes. Of the 8,717 predicted genes, 8,604 are protein-coding.

The team also identified 287 genes across 27 candidate biosynthetic gene clusters, including genes associated with pathways that produce specialized metabolites.

Piscataway, N.J. – September 28, 2026 -- Sampled has secured a five-year contract worth up to $27.1 million from the Department of Veterans Affairs to provide genomics analyses for the Million Veteran Program (MVP), one of the world's largest research initiatives of its kind.

MVP has enrolled more than one million veterans since its 2011 launch

The program studies how molecular factors, lifestyle, and service-related experiences drive elevated veteran health risks, including PTSD, cardiovascular disease, and cancer. Published MVP findings have already advanced understanding of PTSD, artery disease, suicide risk, stroke, and substance use.